Neoadjuvant_cisplatin_plus_vinblastine_chemotherapy_in_locally_advanced_non-small_cell_lung_cancer._Twenty-eight_patients_with_locally_advanced,_unresectable_non-small_cell_lung_cancer_(NSCLC)_received_neoadjuvant_chemotherapy_with_cisplatin_(120_mg/m2_on_days_1_and_29)_and_vinblastine_(4_mg/m2_weekly_for_6_weeks)._At_the_completion_of_induction_chemotherapy,_all_patients_were_assessed_for_resectability._Those_patients_judged_to_be_resectable_underwent_thoracotomy._All_remaining_patients_received_thoracic_radiation_therapy_(5500_cGy)_followed_by_additional_chemotherapy_in_those_patients_responding_to_neoadjuvant_treatment._There_were_15_partial_responses_to_neoadjuvant_chemotherapy_for_an_overall_response_rate_of_54%_(95%_confidence_interval,_36%_to_71%)._Only_five_partially_responding_patients_(18%)_were_thought_to_have_had_sufficient_tumor_regression_to_allow_for_a_potentially_curative_resection._However,_a_complete_resection_was_done_in_only_two_patients._Overall_median_survival_was_12_months_(range,_4_to_72_months)_with_1-year,_2-year,_and_3-year_survival_rates_of_54%,_39%,_and_11%,_respectively._The_primary_toxicity_associated_with_neoadjuvant_chemotherapy_was_moderate_to_severe_(Eastern_Cooperative_Oncology_Group_Grade_3_or_4)_nausea_and_emesis_in_25%_of_patients._Hematologic_toxicity_was_relatively_modest;_only_one_patient_had_Grade_4_leukopenia_(less_than_1000/microliter)._Fever_and_neutropenia_were_uncommon,_and_there_were_no_documented_septic_episodes_or_treatment-related_deaths._Compared_with_historic_controls_treated_with_radiation_therapy_alone,_cisplatin-based_neoadjuvant_chemotherapy_appeared_to_improve_the_median_and_long-term_survival_of_Stage_III_NSCLC_patients_modestly.